10x Genomics (TXG) Cash from Investing Activities (2018 - 2026)

10x Genomics (TXG) has 9 years of Cash from Investing Activities data on file, last reported at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 30.74% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$12.9 million (up 71.53% YoY), and the FY2025 full-year result was -$13.4 million, up 58.82% from the prior year.
• Cash from Investing Activities advanced to -$1.3 million in Q1 2026, from -$1.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $120.0 million in Q1 2023 to a low of -$257.6 million in Q1 2022.
• A 5-year average of -$15.6 million and a median of -$1.9 million in 2025 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 367.75% in 2024, while the deepest fall reached 493.89% in 2024.
• Tracing TXG's Cash from Investing Activities over 5 years: stood at -$33.2 million in 2022, then soared by 139.49% to $13.1 million in 2023, then slumped by 493.89% to -$51.6 million in 2024, then surged by 96.5% to -$1.8 million in 2025, then climbed by 27.37% to -$1.3 million in 2026.
• Business Quant data shows TXG's Cash from Investing Activities at -$1.3 million in Q1 2026, -$1.8 million in Q4 2025, and -$8.8 million in Q3 2025.